Mounting Evidence for Ki67 as Independent Prognostic Marker

TON - January 2017, Vol 10, No 1 - Breast Cancer
Alice Goodman

Copenhagen, Denmark—Measuring the Ki67 protein, along with traditional risk factors such as tumor size and molecular characteristics, may make it possible to avoid sentinel node biopsy in women aged >50 years with breast cancer. Higher Ki67 values were associated with larger tumor size and increased likelihood of axillary node metastasis in women aged ≥50 years, regardless of hormone receptor status or HER2 status, reported investigators at the recent European Society for Medical Oncology Congress.

“We may have found an indirect way of evaluating nodal status in a small subset of patients, thus sparing them some invasive procedures,” said lead investigator Giacomo Bregni, MD, IRCCS AOU San Martino and the IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

The Ki67 protein is a marker of cell proliferation that indicates tumor aggressiveness. However, routine use of Ki67 as a marker remains controversial.

Several studies have shown that Ki67 is an independent prognostic factor in patients with breast cancer, and Ki67 is included in the Oncotype DX test that estimates the likelihood of breast cancer recurrence and the need for chemotherapy. A survey in the United States that included oncologists (66%), nurses and oncology nurses (15%), physician assistants and nurse practitioners (6%), and other healthcare practitioners showed that 70% would include Ki67 in the pathology report and 49% would use Ki67 status to guide treatment selection. Further, a recent study found that a Ki67 value of <40% predicted for favorable disease-free survival, whereas >40% was associated with more aggressive disease.1

The study presented at the European Society for Medical Oncology Congress was based on 1785 patients treated for early breast cancer (stages T1-2, N0-N1) at the National Cancer Institute of Milan. In that study, higher Ki67 values were significantly associated with larger tumor size and increased likelihood of axillary lymph node metastases in women aged ≥50 years (P <.001), with no substantial differences according to hormone receptor or HER2 status, whereas no association was found be­tween Ki67 values and axillary lymph node metastases in patients aged <50 years or with smaller tumors (<10 mm). The odds of axillary lymph node metastases increased by 42% for each additional 5-mm increase in tumor size in all breast cancers except triple-negative cancers.

“Ongoing studies are evaluating axillary surgery and sentinel node biopsy in breast cancer, and it could be worthwhile to consider stratification based on tumor size and molecular characteristics, including Ki67,” Dr Bregni told listeners.

He added that it may be redundant to discuss axillary surgery in patients with exceptionally good prognosis, and in patients with poor prognosis who will be offered chemotherapy and radiation. Clinical trials should consider evaluating whether axillary surgery and sentinel node biopsy can be avoided in patients aged >50 years with small tumors, low Ki67, and triple-negative breast cancer, Dr Bregni suggested.

Commenting on this study, Giuseppe Viale, MD, University of Milan and European Institute of Oncology, said, “Sentinel node biopsy is the standard of care for local treatment of patients with clinically node–negative early breast cancer because it allows us to spare unnecessary complete axillary node dissection. However, approximately 70% of patients will have a negative sentinel node biopsy, raising the question of whether we can identify patients for whom sentinel node biopsy might be avoided.”

“The present, single-institution study is hypothesis-generating, and suggests that patients with exceptionally good prognosis according to age, tumor size, and low Ki67, as well as triple-negative patients, are at such a low risk of axillary node metastases that they may be spared sentinel lymph node biopsy,” Dr Viale concluded.

Source: Wang J, Sang D, Xu B, et al. Value of breast cancer molecular subtypes and Ki68 expression for the prediction of efficacy and prognosis of neoadjuvant chemotherapy in a Chinese population. Medicine (Baltimore). 2016;95:e3518.

Related Items
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancers
Wayne Kuznar
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Breast Cancer
Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer
Phoebe Starr
TOP - November 2017, Vol 10, No 4 published on November 13, 2017 in Breast Cancer
Patient-Reported Outcomes Influence Radiation Guidelines
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Hair Loss Seen in 1 of 3 Women with Breast Cancer Receiving Endocrine Therapy
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Conference Correspondent
Adverse Events Associated with Checkpoint Inhibitors
Alice Goodman
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Adverse Effects
No Advantage to Dual HER2 Blockade in Early-Stage Breast Cancer
TON Web Exclusives published on August 21, 2017 in Breast Cancer
Adding a Second Anti-HER2 Agent Appears Beneficial in Women with Early-Stage, HER2-Positive Breast Cancer at High Risk for Recurrence
TON Web Exclusives published on August 21, 2017 in Breast Cancer
Pembrolizumab Continues to Show Durable Activity in Triple-Negative Breast Cancer
TON Web Exclusives published on August 21, 2017 in Breast Cancer
Nine-Week Course of Adjuvant Trastuzumab Therapy May Be an Option for Women with Low-Risk Hormone Receptor–Positive Breast Cancer
TON Web Exclusives published on August 21, 2017 in Breast Cancer
Two Randomized Studies Add to Body of Data Showing Equivalence of Trastuzumab Biosimilars
TON Web Exclusives published on August 21, 2017 in Breast Cancer
Last modified: February 2, 2017